SAL0195
/ Shenzhen Salubris
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2026
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0195 Injection in Participants With or Without Elevated Lipoprotein(a)
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: The Third Xiangya Hospital of Central South University
New P1 trial
1 to 1
Of
1
Go to page
1